Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Ezra, Rodin, Danielle, Sutradhar, Rinku, Nofech-Mozes, Sharon, Trebinjac, Sabina, Paszat, Lawrence Frank, Rakovitch, Eileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297044/
https://www.ncbi.nlm.nih.gov/pubmed/37366916
http://dx.doi.org/10.3390/curroncol30060433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297044/
https://www.ncbi.nlm.nih.gov/pubmed/37366916
http://dx.doi.org/10.3390/curroncol30060433

Ejemplares similares